BackgroundStudies have shown that COVID-19 could lead coagulation defects, resulting
in increased morbidity and mortality. In this study, we sought to estimate the prevalence
of deep vein thrombosis (DVT) among COVID-19 hospitalizations and its effects on hospital
outcomes using a large administrative database.MethodsWe conducted a retrospective
analysis of the 2020 California State Inpatient Database. All hospitalizations >=
18 years and primary diagnosis of COVID-19 were included and were stratified into
those with and without DVT. The main outcomes of the study were in-hospital mortality,
prolonged length of stay, vasopressor use, mechanical ventilation, and intensive care
unit admission.ResultsWe included a total of 94,114 primary COVID-19 hospitalizations
for the analysis. Among them, 1575 (1.7%) had DVT. After adjusting for covariates,
regression analysis showed that those with DVT had significantly greater odds for
mortality (adjusted odds ratio [aOR], 2.34; 95% confidence interval [CI], 2.07-2.65),
prolonged length of stay (aOR, 3.51; 95% CI, 3.16-3.91), vasopressor use (aOR, 4.23;
95% CI, 3.78-4.74), mechanical ventilation (aOR, 2.90; 95% CI, 2.38-3.53), and intensive
care unit admission (aOR, 4.32; 95% CI, 3.85-4.84).ConclusionsIn our cohort, though
only a few COVID-19 hospitalizations had DVT, the risk for adverse outcome was significantly
higher. Therefore, healthcare providers should promptly monitor for DVT among COVID-19
patients and manage it promptly.
